# Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function

> **NCT00543075** · PHASE1 · COMPLETED · sponsor: **Genta Incorporated** · enrollment: 23 (actual)

## Conditions studied

- Normal Renal Function
- Mildly Impaired Renal Function
- Moderately Impaired Renal Function

## Interventions

- **DRUG:** Genasense (oblimersen, G3139)

## Key facts

- **NCT ID:** NCT00543075
- **Lead sponsor:** Genta Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-11
- **Final completion:** 2009-09
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2012-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00543075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00543075, "Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00543075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*